ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ ПОСРЕДСТВОМ ЭКСПРЕССИИ ФЕРМЕНТА, ОБЛАДАЮЩЕГО ДЕЗОКСИРИБОНУКЛЕАЗНОЙ (ДНКазной) АКТИВНОСТЬЮ, В ПЕЧЕНИ

Изобретение относится к лечению заболевания или состояния у субъекта, сопровождающегося накоплением внеклеточной ДНК (вкДНК) в порто-синусоидальном кровотоке печени. Предложен способ лечения вышеуказанного заболевания или состояния у субъекта, включающий введение субъекту терапевтически эффективного количества рекомбинантного вектора экспрессии аденоассоциированного вируса (rAAV), содержащего (i) белок капсида и (ii) нуклеиновую кислоту, содержащую печень-специфичный промотор, функционально связанный с нуклеотидной последовательностью, кодирующей фермент, имеющий дезоксирибонуклеазную (ДНКазную) активность. Также предложен способ лечения вышеуказанного заболевания или состояния у субъекта, включающий введение субъекту вектора экспрессии, содержащего нуклеиновую кислоту, содержащую промотор, функционально связанный с последовательностью, кодирующей фермент, имеющий ДНКазную активность, где промотор является печень-специфичным промотором и/или где вектор включает одну или более молекул, нацеливающих ...

РАСШИРЕННАЯ АДОПТИВНАЯ КЛЕТОЧНАЯ ТЕРАПИЯ

Настоящее изобретение относится к биотехнологии. В частности, изобретение относится к терапии злокачественных опухолей человека. Более конкретно, настоящее изобретение относится к онколитическим аденовирусным векторам отдельно или вместе с терапевтическими композициями для терапевтического применения и к способам терапии злокачественных опухолей. В одном из аспектов настоящее изобретение относится к отдельному введению адоптивной клеточной терапевтической композиции и онколитических аденовирусных векторов. Кроме того, настоящее изобретение относится к фармацевтическому набору и фармацевтической композиции, в которых используют онколитические аденовирусные векторы. 3 н. и 2 з.п. ф-лы, 51 ил., 15 пр.

НАБОР РЕКОМБИНАНТНЫХ ГЕНЕТИЧЕСКИХ ВЕКТОРОВ, КОДИРУЮЩИХ ШИРОКО НЕЙТРАЛИЗУЮЩИЕ АНТИТЕЛА ПРОТИВ ВИЧ-1, ИММУНОБИОЛОГИЧЕСКИЙ ПРЕПАРАТ ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ВИЧ-ИНФЕКЦИИ И СПОСОБ ЕГО ПРИМЕНЕНИЯ

Изобретение относится к области биотехнологии, а именно к рекомбинантным генетическим векторам на базе аденоассоциированного вируса, кодирующим широко нейтрализующие антитела против вируса иммунодефицита человека (ВИЧ-1), а также к иммунобиологическим препаратам на их основе для лечения и профилактики ВИЧ-инфекции за счет обеспечения длительной персистенции широко нейтрализующих антител против ВИЧ-1. Описан набор рекомбинантных генетических векторов, кодирующих широко нейтрализующие антитела против ВИЧ-1, направленные на разные эпитопы вирусного белка Env, где в качестве рекомбинантного генетического вектора используется аденоассоциированный вектор серотипа 9. Представлен иммунобиологический препарат для лечения или профилактики ВИЧ-1-инфекции, содержащий комбинацию нескольких аденоассоциированных векторов серотипа 9, выбранных из набора. Также раскрыт способ применения иммунобиологического препарата, характеризующийся тем, что препарат вводят внутримышечно в виде смеси аденоассоциированных ...

Asthma preparation

A preventive or therapeutic agent for asthma, comprising HGF or its salt as an active ingredient.

Oncolytic adenoviruses with increased levels of the E1B-156R isoform

Oncolytic adenoviruses armed with heterologous genes

The present disclosure relates to a group B adenovirus comprising a sequence of formula (I): 5'ITR-B1-BA-B2-BX-BB-BY-B3-3'ITR wherein: B1 is bond or comprises: E1A, E1B or E1A-E1B; BA comprises-E2B-L1-L2-L3-E2A-L4; B2 is a bond or comprises: E3; BX is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; BB comprises L5; BY is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; B3 is a bond or comprises: E4; wherein at least one of BX or BY is not a bond, pharmaceutical compositions comprising the same and use of the viruses and compositions in treatment, particularly in the treatment of cancer. The disclosure also extends to plasmids and processes employed to prepare the said viruses.

Vector

Chimeric type 5/type 11 or type 35 adenovirus vector for preventing infection with antihuman immunodeficiency virus

USE FROM INTERLEUKIN-12 TO THE TREATMENT OF NERVE DAMAGE

ADENOVIRALE VECTORS, SPECIFIC TO CELLS, THE ANDROGEN RECEPTOR EXPRIMIEREN, AND METHODS FOR YOUR USE

MORE CELL-SPECIFICALLY EXPRESSIONS /REPLIKATIONSVEKTOR

ADENOVIRUS FORMULATIONS TO THE GENE THERAPY

VIRUSES WITH INCREASED ONE LYTI KRAFT

COMBINED GENE THERAPY FOR THE TREATMENT OF MACROSCOPIC GLIOMA

PREVENTIVE/THERAPEUTIC MEANS FOR NEURODEGENERATIVE ILLNESSES

ANTI-CANCER MEANS

PROCEDURES FOR DESTROYING TUMORS AND TUMOR-ASSOCIATED ENDOTHELIALZELLEN WITH ADENOVIRALEN MUTANTEN

USE FROM INTERLEUKIN-12 TO THE TREATMENT OF NERVE DAMAGE

USE FROM INTERLEUKIN-12 TO THE TREATMENT OF NERVE DAMAGE

USE FROM INTERLEUKIN-12 TO THE TREATMENT OF NERVE DAMAGE

USE FROM INTERLEUKIN-12 TO THE TREATMENT OF NERVE DAMAGE

USE FROM INTERLEUKIN-12 TO THE TREATMENT OF NERVE DAMAGE

USE FROM INTERLEUKIN-12 TO THE TREATMENT OF NERVE DAMAGE

USE FROM INTERLEUKIN-12 TO THE TREATMENT OF NERVE DAMAGE

USE FROM INTERLEUKIN-12 TO THE TREATMENT OF NERVE DAMAGE

Donor repair templates multiplex genome editing

The present disclosure provides improved multiplex genome editing compositions and methods. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of a hemoglobinopathy, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.

Adeno-associated virus compositions for restoring PAH gene function and methods of use thereof

Provided herein are adeno-associated virus (AAV) compositions that can restore phenylalanine hydroxylase (PAH) gene function in cell. Also provided are methods of use of the AAV compositions, and packaging systems for making the AAV compositions.

Highly efficient transduction and lateral spread in the retina by a novel AAV virus enhanced by rational design

The disclosure provides rAAV particles comprising a new capsid variant, AAV44.9(E531D). The disclosure also provides rAAV particles comprising AAV44.9(E531D) for treatment of the eye, including treatment of retinal disorders. In particular embodiments, the disclosure provides rAAV particles comprising an AAV44.9(E531D) capsid that exhibits enhanced lateral spread after subretinal injection to a fovea of the subject, wherein detachment of the fovea is minimized. The disclosure further provides rAAV particles comprising an AAV44.9(E531D) capsid and a polynucleotide encoding a heterologous nucleic acid sequence. Methods of treatment comprising administering rAAV particles to a mammal in need thereof, and methods of transducing photoreceptor and RPE cells with rAAV particles, are also provided.

Oncolytic virus and method

An oncolytic virus (for example a replication competent virus) comprising a transgene cassette encoding an anti-CD40 antibody or binding fragment thereof, wherein the transgene cassette comprises an amino acid sequence given in SEQ ID NO: 12 or a sequence at least 95% identical thereto (such as 96, 97, 98 or 99% identical thereto), in particular a cassette of SEQ ID NO: 12; pharmaceutical compositions comprising the same, methods of preparing said oncolytic virus and compositions and use of the oncolytic virus or composition in treatment, in particular in the treatment of cancer. Also provided is the treatment of a patient population characterised as having a cancer expressing CD40, in particular a cancer over expressing CD40, with a therapy according to the present disclosure.

Process for producing cytotoxic lymphocyte

The present invention relates to methods for preparing or inducing a cytotoxic lymphocyte having an antigen-specific cytotoxic activity. Some embodiments 5 include the step of co-culturing an antigen-presenting cell and a precursor cell being capable of differentiating into a cytotoxic lymphocyte in the presence of a fibronectin fragment or a mixture thereof. Other embodiments include the step of expanding the cytotoxic lymphocyte in the presence of a fibronectin fragment or a mixture thereof.

DRUG FOR AUDITORY DYSFUNCTION

Oncolytic adenoviruses for treating cancer

The invention relates to an oncolytic adenovirus that comprises a sequence that encodes a hyaluronidase enzyme inserted in the genome thereof. This adenovirus is distributed more efficiently through the mass of the tumour and consequently the oncolytic effect is enhanced. Endovenous injection of the oncolytic adenovirus of the invention gives rise to regressions in tumour volume. Therefore, the oncolytic adenovirus of the present invention can be used to treat cancer or a pre-malignant stage thereof.

Multivalent vaccines comprising recombinant viral vectors

C:\NRPorbI\DCC\AMC75969_1 DOC-1IM2/2011 The invention relates to vaccines comprising recombinant vectors, such as recombinant adenoviruses. The vectors comprise heterologous nucleic acids encoding for at least two antigens from one or more tuberculosis-causing bacilli. The invention also relates to the use of specific protease recognition sites linking antigens through which the encoded antigens are separated upon cleavage. After cleavage, the antigens contribute to the immune response in a separate manner. The recombinant vectors may comprise a nucleic acid encoding the protease cleaving the linkers and separating the antigens. The invention furthermore relates to the use of genetic adjuvants encoded by the recombinant vectors, wherein such genetic adjuvants may also be cleaved through the presence of the cleavable linkers and the specific protease.

Process for producing cytotoxic lymphocyte

Oncolytic adenoviral vectors and methods and uses related thereto

The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies. More specifically, the present invention relates to oncolytic adenoviral vectors and cells and pharmaceutical compositions comprising said vectors. The present invention also relates to a use of said vectors in the manufacture of a medicament for treating cancer in a subject and a method of treating cancer in a subject. Furthermore, the present invention relates to methods of producing GM-CSF in a cell and increasing tumor specific immune response in a subject, as well as uses of the oncolytic adenoviral vector of the invention for producing GM-CSF in a cell and increasing tumor specific immune response in a subject.

Methods for preventing plastic-induced degradation of biologicals

The present invention provides methods for protecting a virus contained in a bioprocess bag from surface-induced degradation, thereby improving the compatibility of viruses with these plastics by preserving quantity and potency of the contained viruses during storage in bioprocess bags over a period of time. It was shown herein that viruses can quickly degrade when stored in bioprocess bags and that the addition of a β-cyclodextrin to a virus-containing solution stored in a bioprocess bag unexpectedly prevents the plastic surface-induced degradation of said virus.

Infectivity-enhanced conditionally-replicative adenovirus and uses thereof

An improved method for the production and purification of adenoviral vectors

An improved method for the production and purification of adenoviral vectors

Replication-competent anti-cancer vectors

Osteocalcin promoter directed adenovirus replicaton for therapy

NOVEL AAV CAPSIDS AND COMPOSITIONS CONTAINING SAME

Provided herein are novel AAV capsids and rAAV comprising the same. In one embodiment, vectors employing a novel AAV capsid show increased transduction of a selected target tissue as compared to a prior art AAV.

MODIFIED ADENOVIRUS AND MEDICINE COMPRISING SAME

... [Problem] The purpose of the present invention is to provide a modified adenovirus having a cytocidal activity on a target cell and high safety. [Solution] The present invention pertains to: a modified adenovirus which comprises an E1A gene, an enhancer sequence having a function of enhancing the expression of the E1A gene, and an AU-rich element introduced into the 3'-untranslated region of a viral gene, which is essentially required for the self-propagation thereof, or a position adjacent to the 3'-untranslated region, or a modified adenovirus which comprises an E1A gene and an enhancer sequence having a function of enhancing the expression of the E1A gene and cannot express normal E4orf6 protein, wherein the distance between the 5'-terminus of the E1A gene and the terminus of the enhancer sequence is 1500-4500 bp; and a medicine comprising the same.

PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING ANTICANCER VIRUS AND HYDROXYUREA AS EFFECTIVE COMPONENTS

The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising an anticancer virus and hydroxyurea as effective components. The pharmaceutical composition for preventing or treating cancer comprising an anticancer virus and hydroxyurea as effective components according to the present invention exhibits superior tumor suppression effect as compared to a conventional case where only an anticancer virus is administered; and can kill even the cancer cells that are resistant to anticancer viruses. Accordingly, the pharmaceutical composition for preventing or treating cancer of the present invention may be beneficially used in treating cancer.

ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR RESTORING PAH GENE FUNCTION AND METHODS OF USE THEREOF

Provided herein are adeno-associated virus (AAV) compositions that can restore phenylalanine hydroxylase (PAH) gene function in cell. Also provided are methods of use of the AAV compositions, and packaging systems for making the AAV compositions.

SYNTHETIC ADENOVIRUSES WITH TROPISM TO DAMAGED TISSUE FOR USE IN PROMOTING WOUND REPAIR AND TISSUE REGENERATION

Synthetic adenoviruses having chimeric fiber proteins and liver detargeting mutations are described. The synthetic adenovirus vectors are capable of specifically infecting cells at wound sites or in regions of damaged tissue. The synthetic adenovirus vectors also are capable of expressing transgenes, such as wound healing factors, at sites of wounded or damaged tissue. Accordingly, the described vectors can be used to detect wounded or damaged tissue, and/or to promote wound healing and regeneration of damaged tissue, such as by expression of heterologous wound healing or tissue regeneration factors.

ADENOVIRUS AND USES THEREOF

Provided herein are adenoviral nucleic acid sequences and adenoviral vectors comprising said nucleic acid sequences. The provided adenoviral vectors can be used to induce a protective immune response in a subject.

ONCOLYTIC VIRUS EXPRESSING INTERFERON AND APPLICATION THEREOF

Provided is an oncolytic virus expressing an interferon. Specifically provided is an oncolytic adenovirus expressing an interferon hybrid protein, said oncolytic virus being capable of effectively suppressing tumors in vitro and in vivo.

COMPOSITIONS AND METHODS FOR MANUFACTURING GENE THERAPY VECTORS

Disclosed are methods for the production and/or purification of a recombinant AAV (rAAV) particle from a mammalian host cell culture.

ARMED REPLICATION-COMPETENT ONCOLYTIC ADENOVIRUSES

Disclosed are replication-competent oncolytic adenoviruses, comprising chimeric human/mouse CD40 ligands. The oncolytic adenoviruses may be replication competent. The chimeric human/mouse CD40 ligand may be MEM40. Also disclosed are methods comprising administering a replication competent oncolytic adenovirus armed with at least one chimeric human/mouse CD40 ligand, for example MEM40, to a patient suffering from a cancer.

THERAPEUTIC AGENT OR DEVELOPMENT INHIBITOR OF POLYGLUTAMINE DISEASE

Disclosed is a therapeutic agent for polyglutamine disease or an inhibitor of the development of polyglutamine disease, which comprises, as an active ingredient, the following component (1) or (2): (1) (i) an HGF protein or (ii) a peptide which is a partial peptide of the HGF protein and which has substantially the same activities as those of the HGF protein, or a salt thereof; or (2) DNA comprising (i) DNA encoding the HGF protein, (ii) DNA encoding a peptide which is a partial peptide of the HGF protein and which has substantially the same activities as those of the HGF protein, or (iii) DNA which can hybridize with DNA having a nucleotide sequence complementary to that of the DNA (i) or (ii) under stringent conditions and which encodes a protein or peptide having substantially the same activities as those of the HGF protein.

EXOGENOUS TAP INHIBITOR "ARMED" ONCOLYTIC VIRUSES AND THERAPEUTIC USES THEREOF

The present invention relates to exogenous TAP inhibitor armed oncolytic viruses that replicate selectively in cancer cells, evade CD8+ cytolytic T-cells, and induce the immune system to recognize tumor cells. Compositions and therapeutic methods using the oncolytic viruses are also provided, including compositions and therapeutic methods for treating cancers, such as melanoma, head and neck cancer, ovarian cancer, breast cancer, glioblastoma, bladder cancer, prostate cancer, lung cancer, liver cancer, colorectal cancer, pancreatic cancer, and renal cancer.

METHODS AND COMPOSITIONS FOR TREATING BRAIN DISEASES

The present disclosure provides methods of treating a disease or delivering a therapeutic agent to a mammal comprising administering to the mammal's cisterna magna and/or ventricle an rAAV particle containing a vector comprising a nucleic acid encoding a therapeutic protein inserted between a pair of AAV inverted terminal repeats in a manner such that cells with access to the cerebrospinal fluid (CSF) express the therapeutic agent and in certain embodiments secretes the therapeutic agent into the CSF for distribution to the brain.

ADENOVIRUS VECTORS SPECIFIC FOR CELLS EXPRESSING ANDROGEN RECEPTOR AND METHODS OF USE THEREOF

Replication-competent adenovirus vectors specific for cells which allow a probasin transcriptional response element (PB-TRE) to function, such as cells which express the androgen receptor (AR), and methods of use of such viruses are provided. These viruses comprise an adenoviral gene under control of a transcriptional regulatory portion of a PB-TRE, which is in turn dependent upon AR expression. The gene can be, for example, a gene required for viral replication or the adenovirus death protein gene (ADP). The viruses can also comprise at least one additional adenoviral gene under control of at least one additional prostate-specific transcriptional response element, such as that controlling prostate-specific antigen expression (PSA-TRE). Thus, virus replication can be restricted to target cells exhibiting prostate-specific gene expression, particularly prostate carcinoma cells. An adenovirus of the present invention can further comprise a heterologous gene such as a reporter under transcriptional ...

ADENOVIRUS VECTORS SPECIFIC FOR CELLS EXPRESSING ANDROGEN RECEPTOR AND METHODS OF USE THEREOF

Replication-competent adenovirus vectors specific for cells which allow a probasin transcriptional response element (PB-TRE) to function, such as cells which express the androgen receptor (AR), and method s of use of such viruses are provided. These viruses comprise an adenoviral gene under control of a transcriptional regulatory portion of a PB-TRE, which is in tum dependent upon AR expression. The gene can be, for example, a gene required for viral replication or the adenovirus death protein gene (ADP). The viruses can also comprise at least one additional adenoviral gene under control of at least o ne additional prostate-specific transcriptional response element, such as that controlling prostate-specific antigen expression (PSA-TRE). Thu s, virus replication can be restricted to target cells exhibiting prostate-specific gene expression, particularly prostate carcinoma cells. An adenovirus of the present invention can further comprise a heterologous gene such as a reporter under transcriptional ...

ONKOLITIChESKII ADENOVIRUS, ENCODING B7

COMPARTMENTALIZED METHOD OF NUCLEIC ACID DELIVERY AND COMPOSITIONS AND USES THEREOF

onkoliticheskie adenoviruses, bearing heterologous genes

СПОСОБ ОБЕСПЕЧЕНИЯ ЗАЩИТЫ АДЕНОВИРУСА ОТ РАЗРУШЕНИЯ, ВЫЗВАННОГО ВЗАИМОДЕЙСТВИЕМ С ПЛАСТИКОМ, И ПРИМЕНЕНИЕ 2-ГИДРОКСИПРОПИЛ--ЦИКЛОДЕКСТРИНА ДЛЯ ЗАЩИТЫ АДЕНОВИРУСА

Изобретение относится к способу защиты аденовируса, вызванного взаимодействием с пластиком, и применению 2-гидроксипропил--циклодекстрина для защиты аденовируса. Описывается способ обеспечения защиты аденовируса от разрушения, вызванного взаимодействием с поверхностью, где указанный аденовирус содержится в растворе, находящемся в мешке, состоящем из пластика, выбранного из группы этиленвинилацетата, полиамида и полиэтилена, и где указанный способ включает стадию добавления 2-гидроксипропил--циклодекстрина к указанному раствору в концентрации от приблизительно 1% (вес./вес.) до приблизительно 30% (вес./вес.). Добавление 2-гидроксипропил--циклодекстрина к раствору, содержащему аденовирус, который хранится в биотехнологическом мешке, неожиданно предотвращает разрушение указанного вируса, вызванное взаимодействием с пластиковой поверхностью.

ОНКОЛИТИЧЕСКИЕ АДЕНОВИРУСЫ, СОДЕРЖАЩИЕ ТРАНСГЕНЫ

Изобретение относится к способным к репликации онколитическим аденовирусам группы В, содержащим трансгены, а также к их применению в терапии рака, в частности, в составе композиции.

아데노바이러스의 생산 방법

... 본 개시내용은 아데노바이러스의 제조 방법 및 당해 방법으로부터 수득가능한 바이러스에 관한 것이며, 당해 방법은 상기 세포를 지지하는데 적합한 배지의 존재하에 상기 아데노바이러스로 감염된 포유동물 세포를 배양함으로써 상기 바이러스가 복제하도록 하는 단계(여기서, 상기 세포는 바이러스 복제를 지지할 수 있다), 및 배양 기간의 말기에 배지로부터 아데노바이러스를 여과에 의해 분리하는 단계(여기서, 바이러스의 분리는 세포 용해 단계에 대해 후속적이지 않다)를 포함한다.

Oligodendrocyte-specific promoter MiRNA specific to PLP1 gene, vector comprising the promoter and/or the miRNA, and pharmaceutical composition comprising the vector

adenovirus armed with binder bispecific T cell (ins)

AAV triple-plasmid system

A triple-plasmid system for producing recombinant adeno-associated viruses is disclosed.

Modified adenoviruses

Disclosed herein are compositions that include modified adenoviruses. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines. Also disclosed herein are viral vectors using TET promoter system and methods of producign viruses having the same.

ONCOLYTIC VIRUS COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER

Provided herein, inter alia, are compositions and methods including recombinant oncolytic viruses expressing CD47 antibody for the treatment of diseases including cancer, immune disorders, and infectious disease.

AN ONCOLYTIC VIRUS VECTOR CODING FOR VARIANT INTERLEUKIN-2 (VIL-2) POLYPEPTIDE

The present invention provides an oncolytic adenoviral vector comprising a nucleic acid sequence encoding a variant interleukin 2 (vIL-2) polypeptide as a transgene. The present invention also provides a pharmaceutical composition comprising said oncolytic vector and at least one of the following: physiologically acceptable carriers, buffers, excipients, adjuvants, additives, antiseptics, preservatives, filling, stabilising and/or thickening agents. A particular aim of the present invention is to provide said oncolytic viral vector or pharmaceutical composition for use in the treatment of cancer or tumor, preferably a solid tumor.

CANCER THERAPY

The invention concerns a modified oncolytic adenovirus; a pharmaceutical composition comprising same; and a method of treating cancer using same.

MODIFIED ONCOLYTIC ADENOVIRUSES

The invention concerns a modified replication competent, oncolytic adenovirus; a pharmaceutical composition comprising same; and a method of treating cancer using same.

PERSONALIZED CANCER VACCINES

The invention provides for a recombinant adenoviral vector comprising a recombinant oncolytic adenovirus which has: (1) a modified transcription regulatory sequence wherein the adenoviral vector is transcriptionally active in cancer cells and/or hyperproliferative cells and transcriptionally attenuated in normal cells, and (2) a transgene encoding one or more cancer antigens that are specific to a subject. The invention further provides a method of producing said recombinant adenoviral vector. The recombinant oncolytic adenoviral vector described above is used in methods of stimulating a heightened immune response against a cancer antigen in a subject or a method of treating cancer in a subject.

COMBINING ADENOVIRUS AND CHECKPOINT INHIBITORS FOR TREATING CANCER

The invention relates to the combination therapy comprising oncolytic adenovirus vector and a checkpoint inhibitor or checkpoint inhibitors. More specifically, the invention relates to oncolytic adenovirus vector and checkpoint inhibitor or checkpoint inhibitors for use in a cancer therapy.

ONCOGENE THERAPEUTIC DRUG

Provided is a novel oncogene therapeutic means. More specifically, provided is a nucleic acid having a structure in which a nucleic acid (A) encoding a protein having a CD44 extracellular function, a nucleic acid (B) encoding a protein having a Notch core region function, and a nucleic acid (C) encoding a protein having an HIF-3α4 function are linked in the order of (A)-(B)-(C).

SEQUENCE ARRANGEMENTS AND SEQUENCES FOR NEOEPITOPE PRESENTATION

Systems and methods are presented that allow for selection of tumor neoepitopes that are then used to generate a recombinant polytope that is optimized for proper trafficking and processing. In preferred methods, the polytope is encoded in a viral expression system that is used as a therapeutic agent.

Method for treating cancer using p38/JTV-1 and method for screening pharmaceutical composition for treating cancer

The present invention relates to a method for treating cancer using p38/JTV-1 and a method for screening pharmaceutical composition for treating cancer. More particularly, this invention relates to the method for treating cancer, which comprises administering the effective amount of p38/JTV-1 protein or a nucleic acid encoding for said protein to the patient and the method for screening a pharmaceutical composition for treating cancer characterized by selecting a substance having an effect on the increase of the activity of the p38/JTV-1 protein and the intracellular level thereof. The method according to the invention can be effectively used to treat cancer through the mechanism of suppressing the proliferation of cancer cells by binding to FBP (FUSE-binding protein) and thereby promoting the ubiquitination of FBP to downregulate c-myc gene, which is a proto-oncogene, and the mechanism of promoting the apoptosis of cells by binding to PDK-1 (phosphoinositide-dependent protein) and thereby ...

Replication-competent anti-cancer vectors

Novel vectors which are replication competent in neoplastic cells and which overexpress an adenovirus death protein are disclosed. Some of the disclosed vectors are replication-restricted to neoplastic cells or to neoplastic alveolar type II cells. Compositions and methods for promoting the death of neoplastic cells using these replication-competent vectors are also disclosed.

Multivalent vaccines comprising recombinant viral vectors

The invention relates to vaccines comprising recombinant vectors, such as recombinant adenoviruses. The vectors comprise heterologous nucleic acids encoding for at least two antigens from one or more tuberculosis-causing bacilli. Also described is the use of specific protease recognition sites linking antigens through which the encoded antigens are separated upon cleavage. After cleavage, the antigens contribute to the immune response in a separate manner. The recombinant vectors may comprise a nucleic acid encoding the protease cleaving the linkers and separating the antigens. Further described is the use of genetic adjuvants encoded by the recombinant vectors, wherein such genetic adjuvants may also be cleaved through the presence of the cleavable linkers and the specific protease.

GENE EDITING OF DEEP INTRONIC MUTATIONS

Provided herein are compositions, methods, kits, and viral particles for treating a disease or disorder associated with a deep intronic mutation using an engineered, non-naturally occurring Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-CRISPR associated (Cas) (CRISPR-Cas) system. In some aspects, provided herein is a self-limiting CRISPER-Cas system.

GROUP B ADENOVIRUS MODIFIED IN THE E4ORF4 REGION

The present disclosure relates to a type B adenovirus wherein E4orf4 is deleted or non-functional and generally having a DNA sequence in the E3 region, in particular viruses of formula (I), compositions containing the virus, for example pharmaceutical formulations of the virus, processes for making the viruses and the compositions and use of any one of the same in treatment, particularly in the treatment of cancer, such as colorectal cancer and ovarian cancer. 5′ITR-B1-BA-B2-BX-BB-BT-B3-3′ITR (I) ...

ENHANCING AAV-MEDIATED TRANSDUCTION OF OCULAR TISSUES WITH HYALURONIC ACID

Disclosed herein are compositions of rAAV particles and methods for administrating rAAV particles having enhanced transduction properties.

Virus-PCION complex having enhanced antitumor effect by using electromagnetic field

The present disclosure relates to a composition for transduction of a virus in a cell by using a crosslinked product of PEGylated magnetic nanoparticles and catechol grafted poly-L-lysine by application of an external magnetic field. When the composition is used, a virus may be delivered into cells more rapidly and efficiently than in intracellular uptake of a virus by CAR-mediated endocytosis.

Oncolytic rhabdovirus

Embodiments of the invention include compositions and methods related to non-VSV rhabdoviruses and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo.

Potent and balanced bidirectional promoter

The invention provides a bidirectional hCMV-CAG4 promoter and recombinant vectors and recombinant virus comprising the bidirectional hCMV-CAG4 promoter operably linked to a first transgene in one direction and to a second transgene in the opposite direction. The invention also provides methods of making and using such recombinant vectors and recombinant virus.

REDIRECTION OF TROPISM OF AAV CAPSIDS

The disclosure relates to compositions, methods, and processes for the preparation, use, and/or formulation of adeno-associated virus capsid proteins, wherein the capsid proteins comprise targeting peptide inserts tor enhanced tropism to a target tissue.

ONCOLYTIC VIRAL VECTORS FOR USE IN THE TREATMENT OF RETINOBLASTOMA

Preparation method of prostate tumor-targeted double-regulated oncolytic adenovirus expressing superantigen gene

CONDITIONING REGIMENS FOR IN VIVO GENE THERAPY

CYTOPATI VIRUSES FOR THE THERAPY AND PROPHYLAXIS OF NEOPLASIA

CYTOPATHI VIRUSES FOR THE THERAPY AND PROPHYLAXIS OF NEOPLASIA

COMPOSITIONS FOR THE INHIBITION OF THE PROLIFERATION AND INFILTRATION OF BRAIN TUMOR CELLS THROUGH EXPRESSION THE AMPA TYPE GLUTAMAT RECEPTOR SUBUNIT

PROCEDURE FOR THE PRODUCTION OF A CYTOTOXIC LYMPHOZYTEN

TREATMENT OF SARKOM WITH HUMANS WITH ADENOVIRUS VECTOR TNF ALPHA

PROCEDURE AND COMPOSITIONS FOR GENE THERAPY

USE OF ADENOVIREN WITH MUTATIONS IN THE VA-GENES FOR THE CANCER THERAPY

ONCOLYTI ADENOVIRUS

USE FROM INTERLEUKIN-12 TO THE TREATMENT OF NERVE DAMAGE

USE FROM INTERLEUKIN-12 TO THE TREATMENT OF NERVE DAMAGE

USE FROM INTERLEUKIN-12 TO THE TREATMENT OF NERVE DAMAGE